M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Novel Immunotherapies for Multiple Myeloma
TL;DR: Clinical approaches to harness the immune system to overcome this defect with a focus on antibody based and adoptive cellular therapies hold enormous potential in the field of multiple myeloma and in the near future can be combined with or even replace the current standard of care.
Journal ArticleDOI
Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study
Alessandra Larocca,Marco Salvini,Lorenzo De Paoli,Nicola Cascavilla,Giulia Benevolo,Monica Galli,Vittorio Montefusco,Tommaso Caravita di Toritto,Anna Baraldi,Stefano Spada,Nicola Giuliani,Chiara Pautasso,Stefano Pulini,Sonia Ronconi,Norbert Pescosta,Anna Marina Liberati,Francesca Patriarca,Claudia Cellini,Patrizia Tosi,Massimo Offidani,Michele Cavo,Antonio Palumbo,Mario Boccadoro,Sara Bringhen +23 more
TL;DR: This phase III study investigated the efficacy and feasibility of dose/schedule-adjusted lenalidomide-dexamethasone therapy followed by lenalidmide maintenance in elderly, intermediate-fit NDMM patients and found no difference in progression-free survival (PFS) and overall survival (OS) was observed.
Journal ArticleDOI
Emerging drugs and combinations to treat multiple myeloma
TL;DR: An overview of the recent use of monoclonal antibodies and immune checkpoint inhibitors for the treatment of myeloma focusing on the role of multi-agent combinations is provided.
Journal ArticleDOI
Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients
Patrizia Falco,Federica Cavallo,Alessandra Larocca,Davide Rossi,Tommasina Guglielmelli,Alberto Rocci,Mariella Grasso,M L M Siez,L De Paoli,Stefania Oliva,Stefano Molica,Roberto Mina,Giulia Benevolo,Pellegrino Musto,Paola Omedè,Roberto Freilone,Sara Bringhen,A. M. Carella,Gianluca Gaidano,Mario Boccadoro,Antonio Palumbo +20 more
TL;DR: RP induction followed by MPR consolidation and RP maintenance showed a manageable safety profile, and reduced the risk of severe hematological toxicity in unfit elderly myeloma patients.
Journal ArticleDOI
Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant
Antonio Palumbo,Patrizia Falco,Maria Teresa Ambrosini,Maria Teresa Petrucci,Pellegrino Musto,Tommaso Caravita,Patrizia Pregno,Alessandra Bertola,Federica Cavallo,Giovannino Ciccone,Mario Boccadoro +10 more
TL;DR: TD improved PFS and OS in myeloma patients relapsing after AT, and Multivariate analysis indicated that TD and age were the only independent risk factors associated with improved outcome.